AnnaStills/stock.adobe.com
Dechra shared earlier this week that it has officially launched its terbinafine and betamethasone acetate otic gel (DuOtic; Dechra) for canine patients. The product received FDA approval in March 2024 and is a first-to-market treatment for canine otitis externa associated with Malassezia pachydermatis. Because DuOtic is an antibioitic-free solution, it gives professionals a new tool to combat canine otitis externa with antimicrobial stewardship in mind.
“We are proud to equip veterinarians with a dedicated solution for yeast-driven otitis externa that is aligned with our antimicrobial stewardship goals,” said Laura Olsen, president, North America at Dechra, in an organizational release.1 “DuOtic is a game-changer for ear infection care that builds on Dechra’s extensive otic portfolio,…